5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
64 citations
,
March 2008 in “Neuropsychopharmacology” 18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
20 citations
,
January 2004 in “PubMed Central” 5α-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT levels.
45 citations
,
February 2005 in “Steroids” Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
October 2022 in “Revista Eletrônica Acervo Médico” 5-Alpha-Reductase Inhibitors can cause negative side effects.
29 citations
,
January 1996 in “Journal of Pharmaceutical Sciences” Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
237 citations
,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
2 citations
,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
20 citations
,
February 2002 in “Expert Opinion on Therapeutic Patents” New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
4 citations
,
September 2022 in “Experimental and Сlinical Urology” 5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
235 citations
,
September 2004 in “The Journal of urology/The journal of urology” Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
124 citations
,
January 1996 in “Dermatology” 5 alpha-reductase inhibitors, like finasteride, are used to treat conditions like prostate issues and skin disorders.
71 citations
,
November 2012 in “Expert Opinion on Drug Safety” 5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.
Finasteride, a medication, is being re-evaluated for its effects and uses.
January 2006 in “Zhongguo yaofang” The market for these drugs is expected to grow.
1 citations
,
November 2015 in “Cochrane library” 5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
May 2007 in “Inpharma Weekly”
February 2020 in “Definitions” 5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
January 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” 111 citations
,
August 2015 in “Reviews in Endocrine and Metabolic Disorders” 5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.